Women's Health Policy

ABORTION IN THE U.S.

KFF infographic explaining who regulates mifepristone, showing four entities and their roles: the U.S. Food and Drug Administration approves and regulates medications for safety and effectiveness; state legislatures pass laws that can restrict or protect access; courts rule on legal cases affecting regulation; and Congress can pass federal legislation influencing regulation.

Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

Louisiana sued the FDA in October 2025, claiming the FDA’s 2023 regulatory change eliminating the requirement that mifepristone be dispensed in-person—allowing it to be mailed or dispensed at retail pharmacies—harm the state's ability to enforce its abortion ban. This brief reviews the Louisiana v. FDA case now before the Supreme Court, and provides an overview of the other pending litigation involving mifepristone, as well as the mounting tension between states seeking to protect abortion and those banning the provision of abortion.

CONTRACEPTIve care IN THE U.S.

New and noteworthy

Over-the-Counter Oral Contraceptive Pills

In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

531 - 540 of 871 Results

  • Women and HIV/AIDS in the United States Tutorial

    Interactive

    This tutorial was produced for kaiserEDU.org, a Kaiser Family Foundation website that ceased production in September 2013. The kaiserEDU.org tutorials are no longer being updated but have been made available on kff.org due to demand by professors who are using the tutorials in class assignments. You may search for other tutorials to view on kff.org. To download this or other tutorials, visit the tutorials archive page.  Slides are available for download using the “Download Slides” link within the…

  • 1 Year Later: Medical Abortion After FDA Approval

    Report

    On September 28, 2000, the Food and Drug Administration (FDA) approved mifepristone (RU486), the first dedicated medical abortion pill regimen. Many advocates on both sides of the abortion debate predicted that arrival of this new option would transform the abortion landscape - for women, for doctors, and for politicians. So, a year later, where are we? Chart Pack

  • A Report on Women and HIV/AIDS In the U.S.

    Report

    This report maps the trajectory of the HIV/AIDS epidemic among women in the United States (U.S.), including the following: key historical epidemiological trends and the important role played by women in the response over time; the current impact of HIV among women in the U.S., including a profile of those most affected by race/ethnicity, age, transmission risk, geography, and other demographics; major sources of prevention, care, and treatment for women with and at risk for…

  • Contraceptive Coverage Under the Affordable Care Act

    Event Date:
    Event

    The Affordable Care Act (ACA) has changed access to health coverage for millions of women across the nation, including a provision requiring most private health insurance plans to provide coverage for prescription contraceptives and services. On Thursday, April 16 at 9:30 a.m. ET, the Kaiser Family Foundation hosted a briefing to release a new report that examines how the ACA's contraceptive coverage provision is being interpreted by health insurance carriers and to discuss the implications for…

  • Coverage of Sexual and Reproductive Health Services in Medicare

    Issue Brief

    This brief describes Medicare coverage of sexual and reproductive health services, including contraception, and compares that coverage with private insurance plans and Medicaid. These benefits are particularly relevant to nearly 1 million women of reproductive age (20-49) who are eligible for Medicare due to having a long-term disability.

  • KFF Examines Implications of Dobbs-era Abortion Bans and Restrictions for Miscarriage or Stillbirth

    News Release

    In a new brief, KFF explores how abortion bans and restrictions in the aftermath of the Supreme Court’s 2022 Dobbs decision can further complicate pregnancy loss.  Pregnancy loss, which includes miscarriage and stillbirth, is common, and for many people, it is a physically, mentally, and emotionally taxing experience. The medical interventions used to manage miscarriages and stillbirths are often the same medicines and procedures used in abortions, which means abortion bans and restrictions can end…

  • Since Dobbs, Few Large Firms Have Changed Their Plan’s Abortion Coverage Policy

    News Release

    According to an analysis of responses to KFF’s Employer Health Benefits Survey in 2023, relatively few (8%) large firms (with 200 or more workers) offering health benefits report reducing or expanding coverage for abortion since the U.S. Supreme Court overturned Roe v. Wade with the Dobbs v. Jackson ruling. Since Dobbs, 3% of these large firms reduced or eliminated coverage for abortion where it is legal. Meanwhile, 12% of large firms whose largest plan covers…

  • The Supreme Court, Medication Abortion, and the FDA: What’s at Stake?

    News Release

    In advance of oral arguments about access to medication abortion before the Supreme Court on March 26, KFF examines how a Court ruling for the plaintiffs would limit access to mifepristone blocking its use in telehealth and distribution through pharmacies, including in states where abortion is legal and protected. In addition, it could potentially weaken the role of the Food and Drug Administration (FDA) in drug reviews—something the Court has never done before. As part…

  • A Gender Gap in Economic Security for Seniors

    From Drew Altman

    Following up on an earlier column for The Wall Street Journal's Think Tank on seniors and poverty, Drew Altman looks at why older women will be more at risk of economic insecurity than men in the future.